Arbutus Biopharma News and Activities
Presence
Arbutus Biopharma develops antiviral medicines and delivery technologies. Its main products and services support drug research for hepatitis B and other infectious diseases for healthcare partners and patients.
Arbutus Biopharma products and services overview:
- Antiviral medicines
- Drug delivery
- RNA therapeutics
- Research services
Revenue: ~$8 million
Employees: 75
Headquarters: Warminster, Canada
Arbutus Biopharma is one of the...
Arbutus Biopharma is a company listed under the stock ticker ABUS (CA).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Arbutus Biopharma
- Lindsay Androski, Chief Executive Officer and Director
- Robert Beardsley, Director
- Roger Sawhney, Director
Create your alert
to follow the executive moves at Arbutus Biopharma.
Pharmaceuticals
Arbutus Biopharma has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Arbutus Biopharma
- RSS News Feeds | Arbutus Biopharma Corporation
- Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference | Arbutus Biopharma Corporation
- Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference | Arbutus Biopharma Corporation
- Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg | Arbutus Biopharma Corporation
- Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference | Arbutus Biopharma Corporation
- Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection | Arbutus Biopharma Corporation
- Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Arbutus Biopharma Corporation
- Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference | Arbutus Biopharma Corporation
- Arbutus to Report Second Quarter 2020 Financial Results | Arbutus Biopharma Corporation
- Press Releases | Arbutus Biopharma Corporation
- View more press releases Close
Social media about Arbutus Biopharma
- Arbutus Biopharma on Wikipedia, Google News & Yahoo Finance
- Arbutus Biopharma on LinkedIn, X (Twitter) & YouTube
